Ocular Therapeutix reports Q3 EPS loss

Ocular Therapeutix reported third-quarter 2026 revenue of $12.9 million and a net loss of $94.8 million, compared with revenue of $14.5 million and a net loss of $69.4 million a year earlier. Cash and cash equivalents totaled $530.6 million at September 30, 2026. The company said its planned AXPAXL…